LUNG
Pulmonx Corp.
NASDAQ · Healthcare · Medical - Devices · US
$2.83
+4.04%Year over year
Reported trailing growth
- Revenue
- -3.2%
- EBITDA
- +32.2%
- EBIT
- +31.1%
- EPS
- +29.1%
- Free cash flow
- +21.5%
- Operating cash flow
- +20.2%
Forward estimates
Based on analyst estimates
- Revenue
- +8.7%
- EBITDA
- +8.5%
- EPS
- +8.9%
Three-year CAGR
- Revenue
- +19.0%
- EBITDA
- +3.4%
- EBIT
- +7.0%
- Net income
- +4.2%
- EPS
- +7.6%
- Free cash flow
- +0.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026